|
|
Article: CPEX Pharmaceuticals Announces Completion of Phase 2 Trial for Urology Drug by Serenity Pharmaceuticals.(Report)
- Article from:
- Clinical Trials Week
- Article date:
- March 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) announced that its development and commercialization partner, Serenity Pharmaceuticals, has completed a Phase 2a clinical study of an intranasal drug candidate delivered using CPEXEs patented drug delivery platform technology for an undisclosed urology drug. During this study, 41 out of the 43 patients treated showed a positive response to treatment. Serenity has also completed an end-of-Phase-2 meeting with the FDA (see also CPEX Pharmaceuticals, Inc.).
oIn less than a year, our partner Serenity has taken this urology drug candidate from the Investigational New Drug application stage through an end-of-Phase-2 meeting,o ...